Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV-101) for the Treatment of B Cell Driven Autoimmune Diseases

Trial Status: closed to accrual

This phase I trial studies the safety and side effects of autologous fully-human anti-CD19 chimeric antigen receptor T-cell (KYV-101) and to see how well it works in treating patients with B cell-driven autoimmune diseases that includes idiopathic inflammatory myopathy, diffuse cutaneous systemic sclerosis (scleroderma), lupus with renal (kidney) involvement or anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis hat has not responded to previous treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which T cells (a type of immune system cell) are changed in the laboratory so they will work to eliminate the cells that can cause the disease inflammation. T-cells are removed from the patient and modified in the laboratory to put new genetic material into the T cells. T cells that have genetic material added are called genetically modified (changed) T cells. Genetic material normally instructs cells to make proteins and to do things like grow and multiply. If the genetically modified T cells recognize and attach to cells that cause the inflammation (called B cells), they may have the ability to become activated and kill them. Both normal and autoimmune disease-causing B cells will be affected. It is likely that not all normal B cells will be killed, and B cell numbers will gradually come back to normal. After the CAR-T cells are gone and are effective, B cells may also be made in the bone marrow. The goal is for the disease-causing B-cells to either not come back or to have a long absence. Giving KYV-101 may be safe, tolerable, and/or effective in treating patients with refractory B-cell driven autoimmune diseases.